Literature DB >> 9074303

Substance abuse and cognitive functioning in schizophrenia.

J Addington1, D Addington.   

Abstract

Individuals with schizophrenia have an increased vulnerability to abuse drugs or alcohol. This vulnerability can interfere with the course and treatment of the disorder and may also have a detrimental effect on already compromised cognitive functioning. This study has a matched, cross-sectional design and compares the social and cognitive functioning and the symptoms of 33 schizophrenia subjects who abuse substances with 33 nonabusing schizophrenia subjects. Subjects were matched on sex, age, and education variables and were all outpatients. Measures of social functioning and quality of life were used. Assessment of cognitive functioning included measures of verbal ability, attention, executive functioning, and verbal and visual memory. Substance-abusing subjects had significantly lower quality of life. There were no other differences between the 2 groups. Several explanations are offered for the lack of observed differences in cognitive functioning.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9074303      PMCID: PMC1188831     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  13 in total

1.  Significance of cocaine history in schizophrenia.

Authors:  S Sevy; S R Kay; L A Opler; H M van Praag
Journal:  J Nerv Ment Dis       Date:  1990-10       Impact factor: 2.254

2.  The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients.

Authors:  M Birchwood; J Smith; R Cochrane; S Wetton; S Copestake
Journal:  Br J Psychiatry       Date:  1990-12       Impact factor: 9.319

3.  Treatment outcome of first episode schizophrenia.

Authors:  J Lieberman; D Jody; S Geisler; J Vital-Herne; J M Alvir; J Walsleben; M G Woerner
Journal:  Psychopharmacol Bull       Date:  1989

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

5.  Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.

Authors:  J M Cleghorn; R D Kaplan; B Szechtman; H Szechtman; G M Brown; S Franco
Journal:  J Clin Psychiatry       Date:  1991-01       Impact factor: 4.384

6.  Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment.

Authors:  S Arndt; G Tyrrell; M Flaum; N C Andreasen
Journal:  Psychol Med       Date:  1992-05       Impact factor: 7.723

7.  Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.

Authors:  K T Mueser; P R Yarnold; D F Levinson; H Singh; A S Bellack; K Kee; R L Morrison; K G Yadalam
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

8.  Drug abuse in schizophrenic patients: clinical correlates and reasons for use.

Authors:  L Dixon; G Haas; P J Weiden; J Sweeney; A J Frances
Journal:  Am J Psychiatry       Date:  1991-02       Impact factor: 18.112

9.  Alcohol use and abuse in schizophrenia. A prospective community study.

Authors:  R E Drake; F C Osher; M A Wallach
Journal:  J Nerv Ment Dis       Date:  1989-07       Impact factor: 2.254

10.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.

Authors:  D W Heinrichs; T E Hanlon; W T Carpenter
Journal:  Schizophr Bull       Date:  1984       Impact factor: 9.306

View more
  18 in total

1.  Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status.

Authors:  Kate B Carey; Michael P Carey; Jeffrey S Simons
Journal:  J Nerv Ment Dis       Date:  2003-05       Impact factor: 2.254

2.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

3.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

4.  Comorbidity: A sign of the times.

Authors:  R T Pivik
Journal:  J Psychiatry Neurosci       Date:  1997-03       Impact factor: 6.186

5.  Ethanol sensitization in a neurodevelopmental lesion model of schizophrenia in rats.

Authors:  Susan K Conroy; Zachary Rodd; R Andrew Chambers
Journal:  Pharmacol Biochem Behav       Date:  2006-08-28       Impact factor: 3.533

6.  Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders.

Authors:  Serge Sevy; Katherine E Burdick; Hema Visweswaraiah; Sherif Abdelmessih; Meredith Lukin; Eldad Yechiam; Antoine Bechara
Journal:  Schizophr Res       Date:  2007-03-26       Impact factor: 4.939

7.  Substance use and cognition in early psychosis.

Authors:  Alissa Pencer; Jean Addington
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

8.  First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group.

Authors:  Kathleen Crebbin; Emma Mitford; Roger Paxton; Douglas Turkington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-01-27       Impact factor: 4.328

9.  Substance abuse and quality of life among severely mentally ill consumers: a longitudinal modelling analysis.

Authors:  Karen A Urbanoski; John Cairney; Edward Adlaf; Brian Rush
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-07-27       Impact factor: 4.328

10.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.